Core Insights - XWELL, Inc. reported first quarter 2025 revenue of approximately $7.0 million, a decrease from $8.7 million in the same period of 2024, primarily due to lower revenues from XpresTest and XpresSpa, offset by new revenue from Priority Pass [9][14] - The company is focused on expanding its wellness offerings through a multi-brand strategy, including plans to acquire medical spas in metropolitan areas and enhance its airport wellness services [4][3] - XWELL secured a three-year extension of its Traveler-based Genomic Surveillance Program with the CDC, aimed at early detection of pathogens in major airport hubs [6][5] Operating Highlights - The company operates 28 XpresSpa locations across major airports, with upgrades to reflect a science-driven approach to wellness [8] - XWELL's revenue for the first quarter included approximately $4.3 million from XpresSpa, $2.2 million from XpresTest, and $552,000 from Naples Wax Center [15] - Total cost of sales decreased by approximately 6% year-over-year, while total operating expenses decreased by approximately 11% [9][19] Financial Condition - As of March 31, 2025, XWELL had approximately $3.7 million in cash and cash equivalents and $7.3 million in marketable securities, with no long-term debt [12] - The operating loss for the first quarter was approximately $3.2 million, compared to $2.4 million in the same quarter of 2024 [20] - The net loss attributable to XWELL for the first quarter was approximately $4.7 million, an increase from $2.5 million in the prior year, attributed to higher one-time expenses [22] Future Plans - The company plans to open a new XWELL location in New York City's Penn Station in mid-2025, designed for quick-access wellness services [11] - XWELL is actively broadening its retail product portfolio to include wellness devices, nutritional supplements, and innovative wellness patches [8] - An investor conference call is planned to discuss growth initiatives and forthcoming programs [23]

Core Viewpoint - Tesla is set to begin testing its robotaxi service in Austin, Texas, by the end of June, with plans to scale up from 10 self-driving cars to about 1,000 within a few months, despite facing regulatory scrutiny regarding safety [1][4][5]. Group 1: Robotaxi Deployment - The initial deployment will focus on the safest parts of Austin, utilizing geofencing to limit operations [2]. - A successful trial is critical for Tesla as the company shifts focus from developing a new cheaper EV platform to launching the robotaxi service and its Optimus humanoid robots [5][8]. - Tesla is in discussions with major automakers to license its Full Self-Driving (FSD) software, which is expected to be integral to the robotaxi service [9]. Group 2: Regulatory Scrutiny - The National Highway Traffic Safety Administration (NHTSA) is investigating Tesla's FSD software due to collisions in reduced visibility conditions, raising questions about the safety of the upcoming robotaxi service [6][8]. - The NHTSA has requested information from Tesla regarding the performance of its robotaxis in poor weather conditions [8]. Group 3: Market Context - Tesla's stock saw a slight increase of less than 1% during afternoon trading, reflecting market sentiment amid the company's strategic pivot [4]. - The commercialization of autonomous vehicle technology remains challenging due to stringent regulations and significant investments, leading to many companies exiting the market [6].

Group 1 - Verisk has elected Christopher J. Perry and Sabra R. Purtill to its Board of Directors, effective immediately [1][2] - Perry is the president of Broadridge Financial Solutions, while Purtill is an experienced executive in insurance and financial services, currently advising at American International Group [1][2] - The addition of Perry and Purtill is expected to enhance Verisk's strategic direction in data analytics and technology for the global insurance industry [2] Group 2 - Verisk is recognized as a leading strategic data analytics and technology partner for the global insurance industry, focusing on improving operational efficiency and underwriting outcomes [3] - The company utilizes advanced data analytics, software, and scientific research to address global risks, including climate change and sustainability [3] - Verisk operates in over 20 countries and promotes an inclusive culture, consistently earning certification as a Great Place to Work [3]

Core Insights - RxSight, Inc. is an ophthalmic medical device company focused on providing customized vision solutions for patients post-cataract surgery [3] - The company will participate in the Stifel Virtual Ophthalmology Forum on May 27, 2025, featuring a fireside chat with management [2] Company Overview - RxSight offers the RxSight® Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL®/LAL+®) and the Light Delivery Device (LDD™), the first adjustable intraocular lens technology available commercially [3] - This technology allows for post-surgery adjustments, enabling personalized vision outcomes for cataract surgery patients [3] Event Participation - The management of RxSight is scheduled for a fireside chat at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time on May 27, 2025 [2] - A live and archived webcast of the presentation will be accessible on the company's investor relations website [2]

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen’s Iqirvo®1 has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis (PBC). This major step unlocks a new milestone payment of €26.5 million under our Licensing and Collaboration Agreement with Ipsen2, due up ...

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund (“we,” “us,” “our,” “CCIF” or the “Fund”) (NYSE: CCIF) today announced its financial results for its second quarter ending March 31, 2025. The full detailed presentation of the Fund’s second quarter 2025 financial results can be viewed on the Fund’s website (carlylecreditincomefund.com/investor-dashboard). Nishil Mehta, CCIF’s Principal Executive Officer and President said, “Our second quarter results reflect the resilient nature of the l ...

Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of directors and shall open the annual general meeting of the Company on 22 May 2025. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 3,957,330 additional shares. In total, Mr. Bøhn will re ...

Start Time: 10:55 January 1, 0000 11:26 AM ET Fiserv, Inc. (NYSE:FI) Barclays 15th Annual Emerging Payments and FinTech Forum May 20, 2025, 10:55 AM ET Company Participants Bob Hau - CFO Takis Georgakopoulos - COO Conference Call Participants Ramsey El-Assal - Barclays Ramsey El-Assal All right, welcome back everybody, and very pleased to have Bob Hau, CFO; and Takis Georgakopoulos, Chief Operating Officer, both from Fiserv. Thank you so much for being here, gentlemen. Bob Hau Absolutely, thank you. Takis G ...

PHOENIX, May 20, 2025 (GLOBE NEWSWIRE) -- DBM Global Inc. (“DBMG”), announced today that it has entered into an amended and restated credit agreement that provides for an $85 million term loan and a $135 million revolving credit facility (the “Credit Facility”), which will be used to fully repay DBMG’s existing debt obligations and provide additional working capital capacity. The Credit Facility from a syndicate led by UMB Bank, N.A. provides for senior secured debt in the total amount of $220 million and i ...

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), has entered into an amended and restated credit agreement that provides for an $85 million term loan and a $135 million revolving credit facility (the “Credit Facility”), which will be used to fully repay DBMG’s existing debt obligations and provide additional working capital capacity. The Credit Facility from a syndicate led by UMB Bank, N.A. provides for seni ...